Key result
Elevated serum miR-675-3p linked to ~5.4-fold higher risk of adverse cardiovascular events in asymptomatic atherosclerosis.
Why the study?
There is an urgent need to develop new and reliable diagnostic and prognostic biomarkers for atherosclerosis to improve early screening and intervention.
Cohort (n=180)
No
Hazard Ratio: 5.375 (95% CI 1.59–18.17)
p-value: p=0.007
May support risk stratification in asymptomatic atherosclerosis; leaves open prospective validation before clinical adoption.
In recent years, a rising number of studies have confirmed that microRNA (miRNA) plays a prominent role in the early diagnosis and prognostic value assessment of cardiovascular diseases. The current study was conducted to examine the expression of miR-675-3p in atherosclerosis (AS) patients and to evaluate its clinical diagnosis and prognostic value. 110 AS patients and 70 healthy controls were included in the study. Serum miR-675-3p levels were detected by quantitative real-time PCR (qRT-PCR). The clinical diagnostic significance of serum miR-675-3p in AS patients were investigated by the receiver operating characteristic (ROC) curve. The correlation between miRNA and carotid intima-media thickness (CIMT) was analyzed by the Spearman correlation coefficient. The prognostic significance of serum miR-675-3p was evaluated by the Kaplan-Meier method and Cox regression analysis. The patient’s serum miR-675-3p was significantly increased than the healthy individuals ( P < 0.05). An increase of carotid intima-media thickness (CIMT) was positively correlated with the promotion of serum miR-675-3p levels. The area under the ROC curve (AUC) was 0.918, with high sensitivity and specificity. miR-675-3p is a key independent predictor of cardiovascular adverse events in AS patients (HR = 5.375, 95%CI = 1.590-18.170, P = 0.007), and patients with elevated miR-675-3p were more likely to have cardiovascular adverse events (log-rank P = 0.030). Increased miR-675-3p can be used as a potential marker for the diagnosis of AS, and was associated with the poor prognosis of AS.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a cohort in Atherosclerosis (n=180). Elevated serum miR-675-3p vs. Low serum miR-675-3p was evaluated on Cardiovascular adverse events (hospitalization or death due to myocardial infarction, stroke, TIA, etc.) (HR 5.375, 95% CI 1.590-18.170, p=0.007). Elevated serum miR-675-3p is a strong independent predictor of cardiovascular adverse events in patients with asymptomatic atherosclerosis (HR 5.375).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: